RP-UFLC based Bioanalytical Method Development, Optimization, and Validation for the Estimation of Isradipine in Rabbit Serum

被引:0
作者
Ghose, Debashish [1 ]
Swain, Suryakanta [2 ]
Patra, Chinam Niranjan [1 ]
Jena, Bikash Ranjan [3 ]
机构
[1] Roland Inst Pharmaceut Sci, Dept Pharmaceut, Berhampur 760010, Odisha, India
[2] KK Univ, Sch Pharm & Paramed Sci, Nalanda 803115, Bihar, India
[3] Centurion Univ Technol & Management, Sch Pharm & Life Sci, Bhubaneswar 751009, Odisha, India
关键词
Critical process parameters; critical analytical attributes; critical method parameters; pharmacokinetics; stability; isradipine; PYRIDINE METABOLITE; RELEASE ISRADIPINE; PHARMACOKINETICS; FORMULATION;
D O I
10.2174/1573411019666230605112048
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Introduction: The objective of this study is to provide a rapid, sensitive, consistent, and cost-effective method for quantifying isradipine using ultra-fast liquid chromatography. Methods: Quality by Design principles will form the basis of this approach, grounded on response surface analysis. Shimadzu liquid chromatographic system equipped with a photodiode array detector and LC solution software was used to conduct the RP-UFLC method development and validation. An ODS C18 (250 x 4.6 mm; 5 mu m) UFLC column was used to complete the analysis. The RSM methodology utilized a central composite design to perform the optimization studies. Results: The mobile phase ratio and flow rate were considered crucial method parameters, as well as the peak area, retention time, and USP plate were considered critical analytical attributes. The optimal conditions for chromatographic separation were followed using 80% acetonitrile and water (20% v/v) as mobile phase, a 1 mL/min flow rate, an injection volume of 20 mu L, 40 degrees C of column oven temperature, and maximum absorption at lambda(max) 254 nm using graphical optimization technique. When examining concentrations between 5 and 150 ng/mL, linearity was observed with an R-2 of 0.999. The method created was validated by employing stability testing per the recommendations provided by ICH Q2 (R1). The analysis of blood serum was modified so that it could be used to examine the pharmacokinetic parameters. Conclusion: As a result, high accuracy, precision, sensitivity, linearity, and robustness were established for predicting the amount of isradipine present in its freeze-dried nano-formulations.
引用
收藏
页码:403 / 416
页数:14
相关论文
共 26 条
  • [1] Beg S., 2021, Design of Experiments for Pharmaceutical Product Development, DOI [10.1007/978-981-33-4351-1_2, DOI 10.1007/978-981-33-4351-1_2]
  • [2] Formulation, evaluation, and pharmacokinetics of isradipine proliposomes for oral delivery
    Bobbala, Sharan Kumar Reddy
    Veerareddy, Prabhakar Reddy
    [J]. JOURNAL OF LIPOSOME RESEARCH, 2012, 22 (04) : 285 - 294
  • [3] DETERMINATION OF ISRADIPINE AND THE OXIDATIVE PYRIDINE METABOLITE IN HUMAN-PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY
    BOUTAGY, J
    RUMBLE, F
    DUNAGAN, F
    [J]. JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1989, 487 (02): : 483 - 488
  • [4] PHARMACOKINETICS AND DYNAMIC-RESPONSE OF PLAIN AND SLOW-RELEASE ISRADIPINE FORMULATIONS IN MODERATELY HYPERTENSIVE PATIENTS
    CHRISTENSEN, HR
    SIMONSEN, K
    KAMPMANN, JP
    [J]. PHARMACOLOGY & TOXICOLOGY, 1993, 73 (05): : 279 - 284
  • [5] DETERMINATION OF ISRADIPINE AND ITS PYRIDINE METABOLITE IN SERUM BY CAPILLARY COLUMN GAS-CHROMATOGRAPHY WITH NITROGEN-SELECTIVE DETECTION
    CHRISTENSEN, HR
    ANGELO, HR
    SKAJAA, K
    [J]. JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1992, 574 (01): : 161 - 165
  • [6] Bioavailability and pharmacokinetics of isradipine after oral and intravenous administration:: Half-life shorter than expected?
    Christensen, HR
    Antonsen, K
    Simonsen, K
    Lindekær, A
    Bonde, J
    Angelo, HR
    Kampmann, JP
    [J]. PHARMACOLOGY & TOXICOLOGY, 2000, 86 (04): : 178 - 182
  • [7] THE PHARMACOKINETICS OF ORAL ISRADIPINE IN NORMAL VOLUNTEERS
    CLIFTON, GD
    BLOUIN, RA
    DILEA, C
    SCHRAN, HF
    HASSELL, AE
    GONASUN, LM
    FOSTER, TS
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 28 (01) : 36 - 42
  • [8] Crowther J.B., 2001, VALIDATION PHARM TES, P415
  • [9] Doat M, 1996, ACTA CARDIOL, V51, P155
  • [10] fda, 2009, PHARM DEV